Brian Gorman

This profile gathers the share dealings of Brian Gorman in Opiant Pharmaceuticals, Inc., where the filings describe the role as chief executive. In total, 8 filings cover trades dated from 14 September 2021 to 2 March 2023.

Both buying and selling appear: 1 purchase worth €21k, against 4 sales worth €55k. Sales outweigh purchases by €34k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 2 share grants. So far in 2023, the count stands at no purchases and 2 sales.

The record was last updated on 3 March 2023 with a transaction (€273k) in Opiant Pharmaceuticals, Inc. The clock since the last published purchase (14 September 2021) now reads 1,860 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.